Back to Clinical Feed
Try:
Front ImmunolInfectious Disease
Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides
04 Jun 20264 min read0 viewsJournal Feed
GIST (Key Takeaways)
- Immune-mediated inflammatory arthritides (IMIA), including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and juvenile idiopathic arthritis, are chronic immune-driven disorders in which long-term malignancy safety has become a key determinant of therapeutic decision-making. Patients with IMIA are not oncologically neutral at baseline; persistent inflammatory burden, smoking exposure, age, and cumulative immunosuppressive treatment all modify cancer susceptibility.
- Against this background, biologic and targeted synthetic disease-modifying antirheumatic drugs may both reduce inflammation-associated oncogenic pressure and attenuate antitumor immune surveillance. In this narrative review, we synthesize current evidence on tumor safety across major biologic classes and Janus kinase inhibitors, with emphasis on data emerging through early 2026.
- Overall, most biologic therapies appear broadly reassuring with respect to overall malignancy, although non-melanoma skin cancer remains the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept. Rituximab retains a favorable profile in patients with prior lymphoproliferative disease, whereas IL-6 and IL-17/23 pathway inhibitors appear largely neutral or reassuring in currently available datasets.
Clinical Editorial
Summary
Frontiers in Immunology published a clinical update in Infectious Disease on 04 Jun 2026.
The item focuses on Tumor safety of biologic agents and targeted therapies in immune-mediated inflammatory arthritides.
Review the original article for the full source wording and details.
Source Reference
Read the full original publication from the source journal or publisher link below.
Related by Condition/Drug
Front ImmunolRelated by Conditionarthritisrheumatoid arthritis
Revisiting B-cell targeted therapies in rheumatoid arthritis: from paradoxical biology to deep immune reset
Infectious Disease • 04 May 2026
Front ImmunolRelated by Conditionarthritisrheumatoid arthritis
Case Report: Hermansky–Pudlak syndrome type 1 with pulmonary involvement in a 62-year-old Caucasian woman with rheumatoid arthritis
Infectious Disease • 27 Apr 2026
Nat ImmunolRelated by Conditionarthritisrheumatoid arthritis
Why regulatory T cells fail to control inflammation in rheumatoid arthritis
Infectious Disease • 18 Jun 2026
Nat ImmunolRelated by Conditionarthritisrheumatoid arthritis
Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases
Infectious Disease • 16 Jun 2026
ClinicalTrialsRelated by Conditionarthritisrheumatoid arthritis
Protocol For The Feasibility Study Of INSPIRE: Informal Caregivers Of Frail RA Patients
Infectious Disease • 17 Mar 2026
BMJ OpenRelated by Conditionarthritisrheumatoid arthritis
Association between joint tenderness, patient-reported joint pain and ultrasound abnormalities in anti-CCP positive individuals at risk of rheumatoid arthritis: a cross-sectional study from a Leeds (UK) cohort
Research Highlights • 04 Jun 2026
Feed Metadata
Source
Frontiers in Immunology
Category
Infectious Disease
Published
04 Jun 2026
Feed Metadata
Source
Frontiers in Immunology
Category
Infectious Disease
Published
04 Jun 2026